The added value of ordinal analysis in clinical trials: An example in traumatic brain injury

Critical Care

Volumn 15, Issue 3, 2011, Pages

  Roozenbeek, Bob ^a,b   Lingsma, Hester F ^b   Perel, Pablo ^c   Edwards, Phil ^c   Roberts, Ian ^c   Murray, Gordon D ^d   Maas, Andrew I R ^a   Steyerberg, Ewout W ^b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADULT; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRAUMATIC BRAIN INJURY; BRAIN INJURY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GLASGOW OUTCOME SCALE; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; BRAIN INJURIES; FEMALE; GLASGOW OUTCOME SCALE; HUMANS; MALE; MIDDLE AGED; RESEARCH DESIGN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955979078     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10240     Document Type: Article

References (27)

1. Maas AI, Roozenbeek B, Manley GT. Clinical trials in traumatic brain injury: past experience and current developments. Neurotherapeutics 2010, 7:115-126. 10.1016/j.nurt.2009.10.022, 20129503.
2. Maas AI, Steyerberg EW, Murray GD, Bullock R, Baethmann A, Marshall LF, Teasdale GM. Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations. Neurosurgery 1999, 44:1286-1298.
3. Narayan RK, Michel ME, Ansell B, Baethmann A, Biegon A, Bracken MB, Bullock MR, Choi SC, Clifton GL, Contant CF, Coplin WM, Dietrich WD, Ghajar J, Grady SM, Grossman RG, Hall ED, Heetderks W, Hovda DA, Jallo J, Katz RL, Knoller N, Kochanek PM, Maas AI, Majde J, Marion DW, Marmarou A, Marshall LF, McIntosh TK, Miller E, Mohberg N, et al. Clinical trials in head injury. J Neurotrauma 2002, 19:503-557. 10.1089/089771502753754037, 1462953, 12042091.
4. Maas AI, Steyerberg EW, Marmarou A, McHugh GS, Lingsma HF, Butcher I, Lu J, Weir J, Roozenbeek B, Murray GD. IMPACT recommendations for improving the design and analysis of clinical trials in moderate to severe traumatic brain injury. Neurotherapeutics 2010, 7:127-134. 10.1016/j.nurt.2009.10.020, 20129504.
5. McHugh GS, Butcher I, Steyerberg EW, Marmarou A, Lu J, Lingsma HF, Weir J, Maas AI, Murray GD. A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project. Clin Trials 2010, 7:44-57. 10.1177/1740774509356580, 20156956.
6. Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, Cottingham R, Svoboda P, Brayley N, Mazairac G, Laloe V, Munoz-Sanchez A, Arango M, Hartzenberg B, Khamis H, Yutthakasemsunt S, Komolafe E, Olldashi F, Yadav Y, Murillo-Cabezas F, Shakur H, Edwards P, . CRASH trial collaborators Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004, 364:1321-1328. CRASH trial collaborators.
7. Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B, Fernandes J, Gogichaisvili T, Golden N, Hartzenberg B, Husain M, Ulloa MI, Jerbi Z, Khamis H, Komolafe E, Laloe V, Lomas G, Ludwig S, Mazairac G, Munoz Sanchez Mde L, Nasi L, Olldashi F, Plunkett P, Roberts I, Sandercock P, Shakur H, Soler C, Stocker R, Svoboda P, Trenkler S, et al. CRASH trial collaborators Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005, 365:1957-1959. CRASH trial collaborators.
8. Senn S, Julious S. Measurement in clinical trials: a neglected issue for statisticians?. Stat Med 2009, 28:3189-3209. 10.1002/sim.3603, 19455540.
9. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007, 38:3055-3062. 10.1161/STROKEAHA.107.488536, 17916765.
10. Valenta Z, Pitha J, Poledne R. Proportional odds logistic regression--effective means of dealing with limited uncertainty in dichotomizing clinical outcomes. Stat Med 2006, 25:4227-4234. 10.1002/sim.2678, 16929469.
11. Murray GD, Barer D, Choi S, Fernandes H, Gregson B, Lees KR, Maas AI, Marmarou A, Mendelow AD, Steyerberg EW, Taylor GS, Teasdale GM, Weir CJ. Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy. J Neurotrauma 2005, 22:511-517. 10.1089/neu.2005.22.511, 15892597.
12. Perel P, Arango M, Clayton T, Edwards P, Komolafe E, Poccock S, Roberts I, Shakur H, Steyerberg E, Yutthakasemsunt S. MRC CRASH Trial Collaborators Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ 2008, 336:425-429. 2249681, 18270239, MRC CRASH Trial Collaborators.
13. Hernandez AV, Steyerberg EW, Butcher I, Mushkudiani N, Taylor GS, Murray GD, Marmarou A, Choi SC, Lu J, Habbema JD, Maas AI. Adjustment for strong predictors of outcome in traumatic brain injury trials: 25% reduction in sample size requirements in the IMPACT study. J Neurotrauma 2006, 23:1295-1303. 10.1089/neu.2006.23.1295, 16958582.
14. Roozenbeek B, Maas AI, Lingsma HF, Butcher I, Lu J, Marmarou A, McHugh GS, Weir J, Murray GD, Steyerberg EW, . IMPACT Study Group Baseline characteristics and statistical power in randomized controlled trials: selection, prognostic targeting, or covariate adjustment?. Crit Care Med 2009, 37:2683-2690. 10.1097/CCM.0b013e3181ab85ec, 19885979, IMPACT Study Group.
15. Steyerberg EW, Bossuyt PM, Lee KL. Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics?. Am Heart J 2000, 139:745-751.
16. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 2006, 332:1080. 1458573, 16675816.
17. Machado SG, Murray GD, Teasdale GM. Evaluation of designs for clinical trials of neuroprotective agents in head injury. European Brain Injury Consortium. J Neurotrauma 1999, 16:1131-1138. 10.1089/neu.1999.16.1131, 10619192.
18. Shannon CE. A mathematical theory of communication. Bell Syst Tech J 1948, 27:379-423. 623-656..
19. den Hertog HM, van der Worp HB, van Gemert HM, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ, Dippel DW, . PAIS Investigators The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol 2009, 8:434-440. 10.1016/S1474-4422(09)70051-1, 19297248, PAIS Investigators.
20. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH, . STICH investigators Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005, 365:387-397. STICH investigators.
21. Maas AI, Murray G, Henney H, Kassem N, Legrand V, Mangelus M, Muizelaar JP, Stocchetti N, Knoller N, . Pharmos TBI investigators Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 2006, 5:38-45. 10.1016/S1474-4422(05)70253-2, 16361021, Pharmos TBI investigators.
22. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM, Whitehead J. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 2000, 355:1949-1954. 10.1016/S0140-6736(00)02326-6, 10859040.
23. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW, . Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators NXY-059 for acute ischemic stroke. N Engl J Med 2006, 354:588-600. 10.1056/NEJMoa052980, 16467546, Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators.
24. Aberegg SK, Richards DR, O'Brien JM. Delta inflation: a bias in the design of randomized controlled trials in critical care medicine. Crit Care 2010, 14:R77. 10.1186/cc8990, 2887200, 20429873.
25. Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957, 2:200-215.
26. Mahoney FI, Barthel DW. Functional Evaluation: the Barthel Index. Md State Med J 1965, 14:61-65.
27. Bath PM, Gray LJ, Collier T, Pocock S, Carpenter J. Optimising Analysis of Stroke Trials (OAST) Collaboration Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke 2007, 38:1911-1915. Optimising Analysis of Stroke Trials (OAST) Collaboration.